Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Works matching IS 09612033 AND DT 2018 AND VI 27 AND IP 2
Results: 23
1
2
Successful use of sequential B-cell depletion therapy in lupus.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 345, doi. 10.1177/0961203317717084
- By:
- Publication type:
- Article
3
Do anti-neutrophil cytoplasmic antibodies play a role in systemic lupus erythematosus (SLE) patients? Analysis of the University College Hospital SLE cohort.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 343, doi. 10.1177/0961203317724218
- By:
- Publication type:
- Article
4
Predictors and outcome of systemic lupus erythematosus (SLE) admission rates in a large teaching hospital in sub-Saharan Africa.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 336, doi. 10.1177/0961203317742710
- By:
- Publication type:
- Article
5
Reversible drug-induced antiphospholipid syndrome.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
6
Medication adherence, depression and disease activity among patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 327, doi. 10.1177/0961203317725585
- By:
- Publication type:
- Article
7
The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 319, doi. 10.1177/0961203317721352
- By:
- Publication type:
- Article
8
3 Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 303, doi. 10.1177/0961203317720526
- By:
- Publication type:
- Article
9
Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 290, doi. 10.1177/0961203317719334
- By:
- Publication type:
- Article
10
Impact of systemic lupus erythematosus on oral health-related quality of life.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 283, doi. 10.1177/0961203317719147
- By:
- Publication type:
- Article
11
Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 273, doi. 10.1177/0961203317719148
- By:
- Publication type:
- Article
12
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 265, doi. 10.1177/0961203317717631
- By:
- Publication type:
- Article
13
Disease-specific quality of life in patients with lupus nephritis.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 257, doi. 10.1177/0961203317717082
- By:
- Publication type:
- Article
14
Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 243, doi. 10.1177/0961203317717083
- By:
- Publication type:
- Article
15
Late-onset systemic lupus erythematosus: Is it "mild lupus"?
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 235, doi. 10.1177/0961203317716789
- By:
- Publication type:
- Article
16
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 225, doi. 10.1177/0961203317716787
- By:
- Publication type:
- Article
17
Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 217, doi. 10.1177/0961203317716318
- By:
- Publication type:
- Article
18
Blocking the VISTA pathway enhances disease progression in (NZB X NZW) F1 female mice.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 210, doi. 10.1177/0961203317716322
- By:
- Publication type:
- Article
19
Interferon alpha gene expression and serum level association with low vitamin D levels in Egyptian female patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 199, doi. 10.1177/0961203317716321
- By:
- Publication type:
- Article
20
Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 190, doi. 10.1177/0961203317716319
- By:
- Publication type:
- Article
21
Depression in systemic lupus erythematosus: gender differences in the performance of the Beck Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D), and Hospital Anxiety and Depression Scale (HADS).
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 179, doi. 10.1177/0961203317713142
- By:
- Publication type:
- Article
22
Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 177, doi. 10.1177/0961203317738227
- By:
- Publication type:
- Article
23
Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study.
- Published in:
- Lupus, 2018, v. 27, n. 2, p. 12, doi. 10.1177/0961203317720527
- By:
- Publication type:
- Article